Skip to main content

CASI Pharmaceuticals, Inc (DE)

CASIDelisted
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0000895051

CASI Pharmaceuticals, Inc (DE) was delisted in 2023; its insiders filed their last Form 4 on Sep 9, 2022; 23 institutions reported holding it in 13F filings for Q4 2022, worth $3.31M in total; no superinvestor held it.

Q3 2021 vs. Q2 2021

How the institutions holding CASI Pharmaceuticals, Inc (DE) changed between Q2 2021 and Q3 2021.

All holders in Q3 2021All holders in Q2 2021

13F holders of CASI: Q2 2021 compared with Q3 2021
MeasureQ2 2021Q3 2021Change
Holders6959−10
Shares46.7M38.7M−8.00M (−17.1%)
Value$72.3M$46.0M−$26.3M (−36.4%)

New holders (10)

Institutions that held CASI Pharmaceuticals, Inc (DE) at the end of Q3 2021 but not at the end of Q2 2021.

Institutions new to CASI in Q3 2021
InstitutionSharesValue% of portfolio
Jacobs Levy Equity Management, Inc730,388$869.0K0.01%
Susquehanna International Group, LLP232,109$276.0K0.00%
Connor, Clark & Lunn Investment Management Ltd.60,904$72.0K0.00%
Bridgeway Capital Management, LLC33,399$40.0K0.00%
Virtu Financial LLC30,560$36.0K0.00%
Citadel Advisors LLC29,423$35.0K0.00%
Qube Research & Technologies Ltd10,512$13.0K0.00%
HighTower Advisors, LLC10,021$12.0K0.00%
Wealthspire Advisors, LLC10,000$12.0K0.00%
Total Clarity Wealth Management, Inc.2,000$2.00K0.00%

Sold out (20)

Institutions that held CASI Pharmaceuticals, Inc (DE) at the end of Q2 2021 and filed for Q3 2021 without it.